ISR Considering the FDA approval the company is a leader at the front lines and most likely will fall in the catagory of a "buyout candidate" were looking down the road at major developments and serious coin.
SoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers and GT Medical Technologies, Inc., today announced the receipt of FDA 510(k) regulatory clearance for the brachytherapy technology, known as GammaTile(TM) Therapy that incorporates proprietary Cesium-131 seeds within customizable collagen-based carriers for the treatment of recurrent brain tumors.
Should be a nice adventure down the path of success and riches.
Market Data 
Markets 
AI
